Back to Search Start Over

Oral vitamin D3 5000 IU/day as an adjuvant in the treatment of atopic dermatitis: a randomized control trial

Oral vitamin D3 5000 IU/day as an adjuvant in the treatment of atopic dermatitis: a randomized control trial

Authors :
José Contreras-Ruiz
Karen Sánchez-Armendáriz
Ana García-Gil
Cesar A. Romero
Marcia Karam-Orante
Denek Balcazar-Antonio
Judith Domínguez-Cherit
Source :
International Journal of Dermatology. 57:1516-1520
Publication Year :
2018
Publisher :
Wiley, 2018.

Abstract

Vitamin D has immunomodulatory effects both in the innate and adaptive immune systems, and there is growing scientific evidence demonstrating its relevance in inflammatory processes such as AD.If vitamin D3 promotes the skin immune system, then it should improve the response to treatment of patients with AD.A randomized, double-blind placebo-controlled clinical trial was conducted, which included 65 patients with AD according to Hanifin-Rajka criteria and the severity scale (SCORAD). The patients were divided into two groups to receive either vitamin D3 5000 IU/day (n = 33) or placebo (n = 32), plus baseline therapy (topical steroid, soap substitute, and emollient) during 3 months.Fifty-eight of the 65 enrolled subjects were included in the analysis. At the end of the intervention, the treated group achieved higher levels of 25(OH)D (P 0.001). At week 12, those patients who registered serum levels of 25(OH)D ≥20 ng/ml, regardless of whether or not they had received supplementation, showed a lower SCORAD compared to those with levels20 ng/ml (P 0.001). Eighty percent of the patients with serum levels20 ng/ml (n = 9) had moderate-severe AD despite standard treatment. Vitamin D levels ≥20 ng/ml associated with baseline therapy strongly favored remission of atopic dermatitis (P = 0.03). No significant differences were found between patients with serum levels of ≥20 ng/ml vs. ≥30 ng/ml.Reaching serum levels of 25(OH)D 20 ng/ml in conjunction with standard therapy is sufficient to achieve a reduction in severity (SCORAD) in patients with AD.

Details

ISSN :
00119059
Volume :
57
Database :
OpenAIRE
Journal :
International Journal of Dermatology
Accession number :
edsair.doi.dedup.....a41e9c746471abbb1b205c9611612016
Full Text :
https://doi.org/10.1111/ijd.14220